Concepedia

Publication | Open Access

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

DOIFull Paper Access

797

Citations

17

References

2019

Year

Dennis J. Slamon, Patrick Neven, Stephen Chia, Peter A. Fasching, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, Francisco J. Esteva, Miguel Martín,
New England Journal of Medicine

Abstract

Ribociclib plus fulvestrant showed a significant overall survival benefit over placebo plus fulvestrant in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. (Funded by Novartis; MONALEESA-3 ClinicalTrials.gov number, NCT02422615.).

References

YearCitations

Page 1